A detailed history of Cullen/Frost Bankers, Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 41 shares of ASND stock, worth $5,591. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41
Previous 3 1266.67%
Holding current value
$5,591
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$113.0 - $153.43 $4,294 - $5,830
38 Added 1266.67%
41 $6,000
Q2 2024

Aug 05, 2024

BUY
$121.07 - $153.67 $363 - $461
3 New
3 $0
Q3 2023

Nov 02, 2023

BUY
$86.5 - $103.97 $8,650 - $10,397
100 New
100 $9,000

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.61B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Cullen/Frost Bankers, Inc. Portfolio

Follow Cullen/Frost Bankers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cullen/Frost Bankers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cullen/Frost Bankers, Inc. with notifications on news.